Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHMSA IVIG Coverage Policy Update 2026 | OpenPayer
    Ask Trek AI about this page
    CurrentHawaii Medical Service Association (HMSA)Policy N/A

    Intravenous Immune Globulin (IVIG)

    Customize your policy alerts

    Sign up for all Hawaii Medical Service Association (HMSA) policy alerts

    Know when Hawaii Medical Service Association (HMSA) releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs HMSA Medicare Advantage coverage and precertification requirements for specified intravenous immune globulin products and covered clinical uses. Coverage is available when the applicable indication-specific criteria are met and the member has no exclusions to the prescribed therapy.

    Policy Summary
    PayerHawaii Medical Service Association (HMSA)
    PolicyIntravenous Immune Globulin (IVIG)
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJun 26, 2026
    Last ReviewMar 1, 2026
    Next Review DateNot specified
    Key ActionObtain precertification for IVIG through the HMSA medical specialty drug policy website fax form.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    16IVIG products listed
    15Covered use categories
    1–6 monthsAuthorization durations
    Medicare AdvantageLine of business

    Covered Indications

    Immunoglobulin deficiencies

    Covered when ANY of the following criteria is met; authorization may be granted for 6 months.

    Immunoglobulin deficiency

    • Low pretreatment IgG: Pretreatment IgG level is below 200 mg/dL< 200 mg/dL
    • Clinical need before threshold: Member has a clinical reason for requiring treatment before the IgG level falls below 200 mg/dL

    Immune/idiopathic thrombocytopenic purpura

    Covered under the applicable ITP pathway.

    ITP pathway

    • ITP in pregnancy

      • Prior-treatment condition: At least one of the following applies: other therapy has failed; other therapy is contraindicated; or the disease is rapidly progressive
    • Acute ITP: Platelet count is below 30,000/µL and IVIG is required to manage an acute bleeding episode; or IVIG is required to increase the platelet count before an invasive surgical procedure; or platelet count is below 20,000/µL and the member is at risk for intracerebral hemorrhage< 30,000/µL or < 20,000/µL as applicable
    • Chronic ITP, first-line treatment: Member is younger than 18 years; or IVIG is used with steroids to evoke a rapid platelet response or avoid splenectomy; or the member has a contraindication to steroids< 18 years when applicable
    • Chronic ITP, subsequent treatment: Platelet counts are persistently at or below 20,000/µL; or the member has had an inadequate response to both splenectomy and steroids≤ 20,000/µL when applicable

    Children with human immunodeficiency virus

    Covered when ALL of the following are met; authorization may be granted for 6 months.

    Pediatric HIV

    • Age is less than 13 years< 13 years
    • CD4 count: CD4+ lymphocyte count is at least 200/µL≥ 200/µL
    • Clinical or immunologic status: Patient is clinically symptomatic or immunologically abnormal

    Myasthenia gravis

    Covered when ALL of the following are met; authorization may be granted for 6 months.

    • Disease severity or treatment failure: Member has experienced rapid disease progression, or other forms of treatment have failed or are contraindicated
    • Dose reduction when improved: If the condition improves with IVIG therapy, the prescriber will attempt to decrease and wean the IVIG dose or frequency of administration
    • Discontinue for nonresponse: If the condition does not improve in a quantitative way following initiation of IVIG therapy, the prescriber will discontinue treatment

    Guillain-Barre syndrome

    Covered when ALL of the following are met; authorization may be granted for 1 month.

    • Disease severity or treatment failure: Member has experienced rapid disease progression, or other forms of treatment have failed or are contraindicated
    • Dose reduction when improved: If the condition improves with IVIG therapy, the prescriber will attempt to decrease and wean the IVIG dose or frequency of administration
    • Discontinue for nonresponse: If the condition does not improve in a quantitative way following initiation of IVIG therapy, the prescriber will discontinue treatment

    Chronic inflammatory demyelinating neuropathy

    Covered when ALL of the following are met; authorization may be granted for 6 months.

    CIDP

    • Expert consultation: Consultation has occurred with a neurologist or rheumatologist who is an expert in CIDP to validate the diagnosis and clarify the need for IVIG treatment
    • Sensory-predominant pain pathway: If presumed CIDP predominantly affects the sensory nerves and the goal of therapy is to control pain, the member has had a measurable response to a therapeutic trial of prednisoneMeasurable response to prednisone
    • Disease severity or treatment failure: Member has experienced rapid disease progression, or other forms of treatment have failed or are contraindicated

    Dermatomyositis

    Covered when ALL of the following are met; authorization may be granted for 6 months.

    • Prior therapy: Other forms of treatment have failed or are contraindicated
    • Dose reduction when improved: If the condition improves with IVIG therapy, the prescriber will attempt to decrease and wean the IVIG dose or frequency of administration
    • Discontinue for nonresponse: If the condition does not improve in a quantitative way following initiation of IVIG therapy, the prescriber will discontinue treatment

    Relapsing-remitting multiple sclerosis

    Covered when ALL of the following are met; authorization may be granted for 6 months.

    • Prior therapy: Other forms of treatment have failed or are contraindicated
    • Dose reduction when improved: If the condition improves with IVIG therapy, the prescriber will attempt to decrease and wean the IVIG dose or frequency of administration
    • Discontinue for nonresponse: If the condition does not improve in a quantitative way following initiation of IVIG therapy, the prescriber will discontinue treatment

    Multifocal motor neuropathy

    Covered when ALL of the following are met; authorization may be granted for 6 months.

    • Expert consultation: Consultation has occurred with a neurologist or rheumatologist who is an expert in CIDP and CIDP variants to validate the diagnosis and clarify the need for IVIG treatment
    • Disease severity or treatment failure: Member has experienced rapid disease progression, or other forms of treatment have failed or are contraindicated
    • Dose reduction when improved: If the condition improves with IVIG therapy, the prescriber will attempt to decrease and wean the IVIG dose or frequency of administration
    • Discontinue for nonresponse: If the condition does not improve in a quantitative way following initiation of IVIG therapy, the prescriber will discontinue treatment

    Autoimmune retinopathy and mucocutaneous blistering diseases

    Covered under the applicable autoimmune retinopathy or biopsy-proven mucocutaneous blistering disease pathway.

    Applicable disease pathway

    • Initial autoimmune retinopathy: Initial treatment of autoimmune retinopathy

      Authorization may be granted for 3 months.

    • Continued autoimmune retinopathy: Member has shown improvement within 3 months from the start of IVIG treatmentImprovement within 3 months

      Authorization may be granted for 6 months.

    • Mucocutaneous blistering disease

      • Prior-treatment pathway: Conventional therapy has failed; or conventional therapy is contraindicated; or disease is rapidly progressive, a clinical response could not be achieved quickly enough with conventional agents, and IVIG will be given in combination with conventional treatment

    Chronic lymphocytic leukemia

    Covered when ALL of the following are met; authorization may be granted for 6 months.

    • Immune deficiency: IgG level is below 600 mg/dL or there is evidence of specific antibody deficiencyIgG < 600 mg/dL
    • Recurrent infection: Member experiences recurrent bacterial infections

    Cytomegalovirus prophylaxis in bone marrow or stem cell transplantation

    Covered when ALL of the following are met; authorization may be granted for 6 months.

    CMV prophylaxis in transplantation

    • Age: Member is at least 20 years old≥ 20 years
    • Medicare-covered indication: Transplantation is for a Medicare-covered indication
    • CMV serostatus and transplant type: Member is cytomegalovirus seropositive before transplantation; or the donor is seropositive and the member is undergoing allogeneic transplantation for a hematologic neoplasm

    Desensitization before kidney or heart transplantation

    Covered; authorization may be granted for 6 months.

    Transplant desensitization: IVIG is requested for desensitization before kidney or heart transplantation

    Antibody-mediated transplant rejection

    Covered; authorization may be granted for 6 months.

    Antibody-mediated transplant rejection: IVIG is requested for prevention or treatment of antibody-mediated rejection of a heart, kidney, or stem cell transplant

    Kawasaki disease

    Covered; authorization may be granted for 1 month.

    Kawasaki disease: IVIG is requested for treatment of Kawasaki disease

    Kawasaki disease

    Authorization may be granted for treatment of Kawasaki disease.

    Kawasaki disease indication: The requested IVIG is for treatment of Kawasaki disease

    Authorization duration is 1 month.

    Clinical Thresholds

    Immunoglobulin deficiencies
    Pretreatment IgG threshold< 200 mg/dL
    Clinical exceptionTreatment may be required before the IgG level falls below 200 mg/dL when there is a clinical reason.
    Authorization duration6 months
    Acute ITP
    Acute ITP platelet threshold< 30,000/µL
    Required circumstanceIVIG is required to manage an acute bleeding episode.
    Authorization duration1 month

    Authorization and Documentation Requirements

    Prior Authorization

    IVIG Precertification Required

    Precertification is required for IVIG. Use the HMSA medical specialty drug policy website to obtain the required fax form and submit the precertification request before treatment.

    Prior Authorization

    Kawasaki Disease Precertification Required

    Precertification is required for Kawasaki disease treatment. Refer to the HMSA medical specialty drug policy website for the applicable fax form and submission instructions.

    Documentation Required

    ITP in Pregnancy: Prior Treatment Requirement

    For ITP in pregnancy, document that at least one qualifying prior-treatment condition is present.

    IVIG Therapy Overview

    Intravenous immune globulin (IVIG) serves two principal roles in this policy. It provides replacement therapy for members with qualifying immunoglobulin deficiencies and provides immunomodulatory treatment for selected hematologic, neurologic, autoimmune, infectious-prophylaxis, and transplant-related conditions.

    Covered immunomodulatory uses include immune/idiopathic thrombocytopenic purpura, pediatric human immunodeficiency virus, myasthenia gravis, Guillain-Barre syndrome, chronic inflammatory demyelinating neuropathy, dermatomyositis, relapsing-remitting multiple sclerosis, multifocal motor neuropathy, autoimmune retinopathy, autoimmune mucocutaneous blistering diseases, chronic lymphocytic leukemia, cytomegalovirus prophylaxis during qualifying transplantation, transplant desensitization, antibody-mediated transplant rejection, and Kawasaki disease. Coverage requires that the applicable indication-specific criteria are met and that the member has no exclusion to the prescribed therapy.

    Initial IVIG Authorization

    Initial IVIG authorization

    Initial IVIG therapy is covered only for the listed indications when the applicable indication-specific criteria and authorization duration are met.

    Covered IVIG indication: Member meets the applicable criteria for one of the following: immunoglobulin deficiency; immune/idiopathic thrombocytopenic purpura; pediatric human immunodeficiency virus; myasthenia gravis; Guillain-Barre syndrome; chronic inflammatory demyelinating neuropathy; dermatomyositis; relapsing-remitting multiple sclerosis; multifocal motor neuropathy; autoimmune retinopathy; autoimmune mucocutaneous blistering disease; chronic lymphocytic leukemia; cytomegalovirus prophylaxis in qualifying bone marrow or stem cell transplantation; desensitization before kidney or heart transplantation; antibody-mediated rejection of a heart, kidney, or stem cell transplant; or Kawasaki disease

    Authorization duration varies by indication from 1 to 6 months.

    Kawasaki disease initial therapy

    Authorization may be granted for treatment of Kawasaki disease.

    Kawasaki disease: The requested IVIG is for treatment of Kawasaki disease

    Ongoing Treatment Requirements

    Autoimmune retinopathy continuation

    Continued autoimmune retinopathy treatment may be authorized when the member has shown improvement within 3 months from starting IVIG.

    Continued autoimmune retinopathy: Member has shown improvement within 3 months from the start of IVIG treatmentImprovement within 3 months

    Authorization may be granted for 6 months.

    Response-based continuation management

    For specified neurologic and inflammatory conditions, ongoing therapy requires response-based dose reduction or discontinuation.

    Response-based continuation: If the condition improves with IVIG, the prescriber will attempt to decrease and wean the IVIG dose or administration frequency; if the condition does not improve quantitatively after initiation, the prescriber will discontinue treatment

    Applies to myasthenia gravis, Guillain-Barre syndrome, chronic inflammatory demyelinating neuropathy, dermatomyositis, relapsing-remitting multiple sclerosis, and multifocal motor neuropathy.

    Prior Treatment Requirements

    IndicationPrior-treatment requirementCoverage
    ITP in pregnancyAt least one must apply: other therapy has failed; the member has a contraindication to other therapy; or the disease is rapidly progressive.Covered when criteria are met
    IndicationRequired treatment history or disease courseCoverage
    Chronic inflammatory demyelinating neuropathy (CIDP)Rapid disease progression, or other treatment has failed or is contraindicated.Covered when criteria are met
    DermatomyositisOther forms of treatment have failed or are contraindicated.Covered when criteria are met
    Relapsing-remitting multiple sclerosis (RRMS)Other forms of treatment have failed or are contraindicated.Covered when criteria are met
    Multifocal motor neuropathy (MMN)Rapid disease progression, or other treatment has failed or is contraindicated.Covered when criteria are met
    IndicationRequired conventional-treatment pathwayCoverage
    Autoimmune mucocutaneous blistering diseaseBiopsy-proven qualifying diagnosis; and at least one applies: conventional therapy has failed; conventional therapy is contraindicated; or disease is rapidly progressive, conventional agents cannot produce a sufficiently rapid response, and IVIG is given with conventional treatment. IVIG must be used for short-term control, not maintenance therapy.Covered when criteria are met
    Policy Summary
    PayerHawaii Medical Service Association (HMSA)
    PolicyIntravenous Immune Globulin (IVIG)
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJun 26, 2026
    Last ReviewMar 1, 2026
    Next Review DateNot specified
    Key ActionObtain precertification for IVIG through the HMSA medical specialty drug policy website fax form.
    SourceLink
    On This Page
    Covered IndicationsClinical ThresholdsAuthorization and Documentation RequirementsIVIG Therapy OverviewInitial IVIG AuthorizationOngoing Treatment RequirementsPrior Treatment Requirements
    Dose reduction when improved:
    If the condition improves with IVIG therapy, the prescriber will attempt to decrease and wean the IVIG dose or frequency of administration
  1. Discontinue for nonresponse: If the condition does not improve in a quantitative way following initiation of IVIG therapy, the prescriber will discontinue treatment
  2. Short-term use: IVIG will be used for short-term control and not as maintenance therapy
  3. Intracerebral hemorrhage risk
    Platelet threshold< 20,000/µL
    Required circumstanceMember is considered to be at risk for intracerebral hemorrhage.
    Authorization duration1 month
    Pregnancy-associated ITP
    Pregnancy-associated ITP threshold< 75,000/µL during the current pregnancy
    Pregnancy requirementMember is pregnant.
    Prior-treatment conditionAt least one must apply: failed other therapy, contraindication to other therapy, or rapidly progressive disease.
    Authorization duration6 months
    Children with HIV
    CD4+ lymphocyte threshold≥ 200/µL
    Age requirement< 13 years of age
    Clinical or immunologic statusPatient is clinically symptomatic or immunologically abnormal.
    Authorization duration6 months
    Chronic lymphocytic leukemia
    CLL IgG threshold< 600 mg/dL
    Alternative immune-deficiency findingEvidence of specific antibody deficiency.
    Infection requirementMember experiences recurrent bacterial infections.
    Authorization duration6 months
    CMV transplant prophylaxis
    Age threshold≥ 20 years
    Transplant requirementMember is undergoing bone marrow or stem cell transplantation.
    Coverage requirementTransplantation is for a Medicare covered indication.
    CMV serostatus requirementMember is cytomegalovirus seropositive before transplantation, or the donor is seropositive and the member is undergoing allogeneic transplantation for a hematologic neoplasm.
    Authorization duration6 months
    • The member has failed other therapy.
    • The member has a contraindication to other therapy.
    • The member has a rapidly progressive form of the disease.
    Documentation Required

    Document Failure or Contraindication of Conventional Therapy

    Where required for the applicable indication, document rapid disease progression or that conventional or other forms of treatment have failed or are contraindicated before requesting IVIG.

    • Myasthenia gravis: rapid progression or failed/contraindicated other treatment.
    • Guillain-Barré syndrome: rapid progression or failed/contraindicated other treatment.
    • CIDP: rapid progression or failed/contraindicated other treatment.
    • Dermatomyositis: failed or contraindicated other treatment.
    • Relapsing-remitting multiple sclerosis: failed or contraindicated other treatment.
    • Multifocal motor neuropathy: rapid progression or failed/contraindicated other treatment.
    • Biopsy-proven autoimmune mucocutaneous blistering disease: failed conventional therapy, contraindication to conventional therapy, or rapidly progressive disease for which conventional agents could not produce a timely clinical response; in the latter case, IVIG must be given with conventional treatment.
    Documentation Required

    CIDP Specialist Validation and Prednisone Response

    For CIDP, document expert specialist involvement and, when presumed CIDP predominantly affects sensory nerves with pain control as the treatment goal, a measurable response to a therapeutic prednisone trial.

    • Consultation with a neurologist or rheumatologist who is an expert in CIDP must validate the diagnosis and clarify the need for IVIG.
    • For the specified sensory-predominant pain presentation, document measurable response to prednisone.
    Documentation Required

    Biopsy-Proven Blistering Disease

    For autoimmune mucocutaneous blistering disease, document that the diagnosis is biopsy-proven and that it is one of the qualifying autoimmune conditions.

    • Qualifying diagnoses: pemphigus vulgaris, pemphigus foliaceus, bullous pemphigoid, mucous membrane pemphigoid (cicatricial pemphigoid), or epidermolysis bullosa acquisita.
    • Retain documentation of the diagnostic biopsy.
    Documentation Required

    CLL Immune Deficiency and Recurrent Infections

    For chronic lymphocytic leukemia, document both an immune deficiency and recurrent bacterial infections.

    • IgG level < 600 mg/dL or evidence of specific antibody deficiency.
    • Recurrent bacterial infections.
    Documentation Required

    CMV Transplant Documentation

    For cytomegalovirus prophylaxis in bone marrow or stem cell transplantation, document all transplant-specific eligibility requirements.

    • Member is ≥ 20 years old.
    • Transplantation is for a Medicare-covered indication.
    • Member is CMV seropositive before transplantation, or the donor is seropositive and the member is undergoing allogeneic transplantation for a hematologic neoplasm.
    Denial Risk

    Criteria or Exclusion Not Satisfied

    Coverage is at risk of denial when the applicable authorization criteria are not satisfied or an exclusion to the prescribed therapy applies.

    • Submit documentation supporting every applicable indication-specific criterion.
    • Confirm that no policy exclusion applies to the prescribed IVIG therapy.
    Denial Risk

    Continuation Requires Response and Tapering

    For continued therapy, document measurable quantitative improvement. If the condition improves, the prescriber must attempt to decrease and wean the IVIG dose or administration frequency; if there is no quantitative improvement after initiation, treatment must be discontinued.

    • Applies to myasthenia gravis, Guillain-Barré syndrome, CIDP, dermatomyositis, relapsing-remitting multiple sclerosis, multifocal motor neuropathy, and autoimmune mucocutaneous blistering disease where continued treatment is requested.
    • Autoimmune retinopathy continued treatment requires improvement within 3 months of starting IVIG.
    • Document response, dose or frequency reduction attempts, and discontinuation when response is absent.
    Denial Risk

    Blistering Disease: Short-Term Control Only

    For biopsy-proven autoimmune mucocutaneous blistering disease, IVIG is authorized for short-term control only and must not be used as maintenance therapy.

    • Document the short-term treatment objective.
    • Do not request IVIG as maintenance therapy.

    Authorization duration is 1 month.